Background: In December 2019, a new coronavirus, named Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2), emerged from China, causing pneumonia
outbreaks first in the Wuhan region and then spread worldwide. Due to a lack of efficient and
specific treatments and the need to contain the epidemic, drug repurposing appears to be the
most efficient tool to find a therapeutic solution.
Objectives: The aim of this study was to summarize in vitro data of current agents used for the
management of SARS-CoV-2 all over the world.
Methods: A literature search of articles from January 2000 until April 2020 was performed
using MEDLINE, EMBASE and the Cochrane Library to assess in vitro data of current or putative
therapies for SARS-CoV-2.
Results: Although in vitro studies are scarce, data regarding chloroquine, hydroxychloroquine,
remdesivir, nitazoxanide, teicoplanin, ivermectin, lopinavir, homoharringtonine, and
emetine seem promising.
Conclusion: Scientists all over the world should work together and increase their efforts in
order to find feasible and efficient solutions against this new global viral threat.